← Leaderboards
Cynthia A Lemere
Brigham And Women'S Hospital
$15,207,972
Attributed
$15,207,972
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,207,972 · 11
By mechanism
R01$8,877,444 · 4
RF1$5,592,535 · 2
R21$475,254 · 1
P51$262,739 · 4
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Gregory P Priebe$4,791,718
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposAmyloid Beta-ProteinMouse ModelS DiseaseComplementProteinsAmyloidReportingNerve DegenerationImmune ResponseBiochemicalImmunotherapyImpaired CognitionBrainCognitiveEnzyme-Linked Immunosorbent AssayAntibodiesDepositionExcisionMicrogliaNeurodegenerative DisordersPlayPreventMonoclonal Antibodies
Grant awards (30)
Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease$833,674
R01 · FY2025 · AG · contact PI
Understanding and Mitigating Vascular Side-Effects Associated with Anti-Amyloid Immunotherapy$783,917
R01 · FY2025 · NS · contact PI
Combination Therapy with Semaglutide and Anti-Amyloid Antibodies for Alzheimers Disease$859,410
R01 · FY2024 · AG · contact PI
Understanding and Mitigating Vascular Side-Effects Associated with Anti-Amyloid Immunotherapy$831,601
R01 · FY2024 · NS · contact PI
Novel Inducible Complement C3 Conditional KO Mouse Models to Investigate Neurodegeneration in AD$3,441,150
RF1 · FY2018 · AG · contact PI
AD Immunotherapy with a Novel CDC-Mutant Anti-Pyroglutamate-3 Abeta Antibody to Avoid Vascular Side Effects$2,151,385
RF1 · FY2018 · AG · contact PI
Pyroglutamate Amyloid-beta as an Immunotherapeutic Target for Alzheimer's Disease$338,088
R01 · FY2015 · AG · contact PI
Pyroglutamate Amyloid-beta as an Immunotherapeutic Target for Alzheimer's Disease$338,890
R01 · FY2014 · AG · contact PI
Generation of a Complement C3 Conditional Knockout Mouse$207,057
R21 · FY2014 · AG · contact PI
Pyroglutamate Amyloid-beta as an Immunotherapeutic Target for Alzheimer's Disease$320,251
R01 · FY2013 · AG · contact PI
Generation of a Complement C3 Conditional Knockout Mouse$268,197
R21 · FY2013 · AG · contact PI
Pyroglutamate Amyloid-beta as an Immunotherapeutic Target for Alzheimer's Disease$155,800
R01 · FY2013 · AG · contact PI
Pyroglutamate Amyloid-beta as an Immunotherapeutic Target for Alzheimer's Disease$336,959
R01 · FY2012 · AG · contact PI
Mucosal Abeta Vaccination: Modulating the Immune Response$308,442
R01 · FY2011 · AG · contact PI
Mucosal Abeta Vaccination: Modulating the Immune Response$320,893
R01 · FY2010 · AG · contact PI
Mucosal Abeta Vaccination: Modulating the Immune Response$345,153
R01 · FY2009 · AG · contact PI
Mucosal Abeta Vaccination: Modulating the Immune Response$324,134
R01 · FY2009 · AG · contact PI
Mucosal Abeta Vaccination: Modulating the Immune Response$46,725
R01 · FY2009 · AG · contact PI
Mucosal Abeta Vaccination: Modulating the Immune Response$324,134
R01 · FY2008 · AG · contact PI
ACTIVE ABETA IMMUNIZATION IN VERVETS$55,151
P51 · FY2008 · RR · contact PI
Mucosal Abeta Vaccination: Modulating the Immune Response$311,069
R01 · FY2007 · AG · contact PI
ACTIVE ABETA IMMUNIZATION IN VERVET$103,634
P51 · FY2007 · RR · contact PI
MUCOSAL ABETA VACCINATION; MODULATING THE IMMUNE RESPONSE$34,958
P51 · FY2006 · RR · contact PI
Mucosal ABeta Vaccination: Modulating the Immune Respon*$420,400
R01 · FY2005 · AG
MUCOSAL ABETA VACCINATION;MODULATING THE IMMUNE RESPONSE$33,521
P51 · FY2005 · RR
Mucosal ABeta Vaccination: Modulating the Immune Respon*$420,400
R01 · FY2004 · AG
MUCOSA ABETA VACCINATION;MODULATING THE IMMUNE RESPONSE$35,475
P51 · FY2004 · RR
Mucosal ABeta Vaccination: Modulating the Immune Respon*$420,400
R01 · FY2003 · AG
Mucosal ABeta Vaccination: Modulating the Immune Respon*$420,011
R01 · FY2002 · AG
Mucosal ABeta Vaccination/Modulating the Immune Response$417,093
R01 · FY2001 · AG